Nakajima Atsushi, Ueda Kyoko, Takaoka Masanori, Yoshimi Yoshiko, Matsumura Yasuo
Department of Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.
J Pharmacol Exp Ther. 2006 Mar;316(3):1038-46. doi: 10.1124/jpet.105.092049. Epub 2005 Nov 23.
We have demonstrated previously that preischemic treatment with FK409 [(+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide], a spontaneous nitric oxide (NO) donor, markedly improves ischemia/reperfusion-induced renal injury. However, there is conflicting information (renoprotective or cytotoxic) as to the contribution of NO to ischemic acute renal failure (ARF). In the present study, we investigated the effect of postischemic treatment with FK409 (1, 3, and 10 mg/kg i.v.) at 6 h after reperfusion on ischemic ARF, in comparison with the preischemic treatment effect. Ischemic ARF was induced by clamping of the left renal artery and vein for 45 min, followed by reperfusion, 2 weeks after contralateral nephrectomy. Renal function in ARF rats markedly decreased at 24 h after reperfusion. Histopathological examination of the kidney of ARF rats revealed severe renal damage. In contrast to the renoprotective effect by preischemic treatment, postischemic treatment with FK409 aggravated the ischemia/reperfusion-induced renal dysfunction and histological damage. Immunohistochemical analysis of renal sections obtained from ARF rats revealed positive staining for nitrotyrosine, a biomarker of peroxynitrite formation, in injured tubular cells, and more intense staining was observed in renal tissues from the animals that received postischemic treatment with FK409. On the other hand, the formation of nitrotyrosine, neutrophil infiltration into renal tissues, and renal superoxide production, all of which were enhanced in ARF rats, were efficiently attenuated by the preischemic treatment with FK409. These results demonstrate that, although preischemic treatment with an NO donor is renoprotective, postischemic treatment with the same agent aggravates the ischemia/reperfusion-induced renal injury, probably through peroxynitrite overproduction.
我们之前已经证明,用自发一氧化氮(NO)供体FK409[(±)-(E)-4-乙基-2-[(E)-羟基亚氨基]-5-硝基-3-己烯酰胺]进行缺血预处理,可显著改善缺血/再灌注诱导的肾损伤。然而,关于NO对缺血性急性肾衰竭(ARF)的作用,存在相互矛盾的信息(肾脏保护或细胞毒性)。在本研究中,我们研究了再灌注6小时后用FK409(1、3和10mg/kg静脉注射)进行缺血后处理对缺血性ARF的影响,并与缺血预处理的效果进行了比较。缺血性ARF通过在对侧肾切除术后2周夹闭左肾动脉和静脉45分钟,然后再灌注来诱导。再灌注后24小时,ARF大鼠的肾功能显著下降。对ARF大鼠肾脏的组织病理学检查显示严重的肾损伤。与缺血预处理的肾脏保护作用相反,FK409进行缺血后处理加重了缺血/再灌注诱导的肾功能障碍和组织学损伤。对从ARF大鼠获得的肾切片进行免疫组织化学分析显示,损伤的肾小管细胞中过氧亚硝酸盐形成的生物标志物硝基酪氨酸呈阳性染色,并且在接受FK409缺血后处理的动物的肾组织中观察到更强的染色。另一方面,ARF大鼠中增强的硝基酪氨酸形成、中性粒细胞浸润到肾组织以及肾脏超氧化物产生,均通过FK409的缺血预处理得到有效减轻。这些结果表明,尽管用NO供体进行缺血预处理具有肾脏保护作用,但用相同药物进行缺血后处理会加重缺血/再灌注诱导的肾损伤,可能是通过过氧亚硝酸盐的过量产生。